157 related articles for article (PubMed ID: 7524764)
1. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.
Goldmacher VS; Bourret LA; Levine BA; Rasmussen RA; Pourshadi M; Lambert JM; Anderson KC
Blood; 1994 Nov; 84(9):3017-25. PubMed ID: 7524764
[TBL] [Abstract][Full Text] [Related]
2. Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.
Goulet AC; Goldmacher VS; Lambert JM; Baron C; Roy DC; Kouassi E
Blood; 1997 Sep; 90(6):2364-75. PubMed ID: 9310487
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CD38 as target for immunotherapy in multiple myeloma.
Vooijs WC; Schuurman HJ; Bast EJ; de Gast GC
Blood; 1995 Apr; 85(8):2282-4. PubMed ID: 7718903
[No Abstract] [Full Text] [Related]
4. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.
La Russa VF; Griffin JD; Kessler SW; Cutting MA; Knight RD; Blattler WA; Lambert JM; Wright DG
Exp Hematol; 1992 May; 20(4):442-8. PubMed ID: 1373688
[TBL] [Abstract][Full Text] [Related]
5. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.
Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J
Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin.
Collinson AR; Lambert JM; Liu Y; O'Dea C; Shah SA; Rasmussen RA; Goldmacher VS
Int J Immunopharmacol; 1994 Jan; 16(1):37-49. PubMed ID: 8150554
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated delivery of p53 results in substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34(+) hematopoietic progenitor cells and normal lymphocytes.
Liu Q; Gazitt Y
Exp Hematol; 2000 Dec; 28(12):1354-62. PubMed ID: 11146157
[TBL] [Abstract][Full Text] [Related]
8. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
10. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
[TBL] [Abstract][Full Text] [Related]
11. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
[TBL] [Abstract][Full Text] [Related]
12. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.
Bergsagel PL; Smith AM; Szczepek A; Mant MJ; Belch AR; Pilarski LM
Blood; 1995 Jan; 85(2):436-47. PubMed ID: 7529064
[TBL] [Abstract][Full Text] [Related]
13. Functional differences between CD38- and DR- subfractions of CD34+ bone marrow cells.
Rusten LS; Jacobsen SE; Kaalhus O; Veiby OP; Funderud S; Smeland EB
Blood; 1994 Sep; 84(5):1473-81. PubMed ID: 7520773
[TBL] [Abstract][Full Text] [Related]
14. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Lambert JM; Goldmacher VS; Collinson AR; Nadler LM; Blättler WA
Cancer Res; 1991 Dec; 51(23 Pt 1):6236-42. PubMed ID: 1718599
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
Schmidberger H; King L; Lasky LC; Vallera DA
Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258
[TBL] [Abstract][Full Text] [Related]
16. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin.
Roy DC; Ouellet S; Le Houillier C; Ariniello PD; Perreault C; Lambert JM
J Natl Cancer Inst; 1996 Aug; 88(16):1136-45. PubMed ID: 8757193
[TBL] [Abstract][Full Text] [Related]
17. Immunotoxin depletion of T cells and its effect on hematopoietic progenitor cells in human cord blood.
Xu M; Lu S; Shen B; Li Y
Chin Med J (Engl); 2001 Apr; 114(4):355-9. PubMed ID: 11780453
[TBL] [Abstract][Full Text] [Related]
18. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
Uckun FM; Haissig S; Ledbetter JA; Fidler P; Myers DE; Kuebelbeck V; Weisdorf D; Gajl-Peczalska K; Kersey JH; Ramsay NK
Blood; 1992 Jun; 79(12):3369-79. PubMed ID: 1375851
[TBL] [Abstract][Full Text] [Related]
19. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.
Roy DC; Perreault C; Bélanger R; Gyger M; Le Houillier C; Blättler WA; Lambert JM; Ritz J
J Clin Immunol; 1995 Jan; 15(1):51-7. PubMed ID: 7539011
[TBL] [Abstract][Full Text] [Related]
20. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
Grossbard ML; Freedman AS; Ritz J; Coral F; Goldmacher VS; Eliseo L; Spector N; Dear K; Lambert JM; Blättler WA
Blood; 1992 Feb; 79(3):576-85. PubMed ID: 1370636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]